Brii Biosciences Limited (HKG:2137)
Hong Kong
· Delayed Price · Currency is HKD 2.090
+0.140 (7.18%)
May 2, 2025, 4:08 PM HKT
Brii Biosciences Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 1,003 | 489.65 | 1,191 | 2,855 | 1,035 | Upgrade
|
| Short-Term Investments | 1,317 | 2,171 | 1,807 | 499.65 | 20 | Upgrade
|
| Cash & Short-Term Investments | 2,320 | 2,661 | 2,997 | 3,355 | 1,055 | Upgrade
|
| Cash Growth | -12.79% | -11.23% | -10.65% | 217.99% | 19.83% | Upgrade
|
| Other Receivables | - | 71.09 | 57.72 | 51.52 | 24.8 | Upgrade
|
| Receivables | - | 71.09 | 57.72 | 51.52 | 24.8 | Upgrade
|
| Other Current Assets | 93.81 | 51.03 | 21.79 | 7.68 | 13.08 | Upgrade
|
| Total Current Assets | 2,414 | 2,783 | 3,077 | 3,414 | 1,093 | Upgrade
|
| Property, Plant & Equipment | 14.3 | 5.61 | 19.52 | 33.44 | 43.92 | Upgrade
|
| Long-Term Investments | 9.2 | 142.44 | 146.03 | 152.03 | 116.55 | Upgrade
|
| Other Intangible Assets | 179.71 | 267.42 | 146.89 | 9.51 | 12.22 | Upgrade
|
| Other Long-Term Assets | 89.3 | - | 2.51 | 2.79 | 2.41 | Upgrade
|
| Total Assets | 2,707 | 3,198 | 3,392 | 3,612 | 1,268 | Upgrade
|
| Accrued Expenses | 52.94 | 68.63 | 150.87 | 205.83 | 486.67 | Upgrade
|
| Current Portion of Leases | 4.9 | 3.16 | 9.5 | 8.97 | 8.02 | Upgrade
|
| Current Income Taxes Payable | 1.19 | 2.01 | 1.86 | 1.65 | 1.02 | Upgrade
|
| Current Unearned Revenue | 16.94 | 50.63 | 54.68 | 52.88 | 69.82 | Upgrade
|
| Other Current Liabilities | 1.46 | 1.44 | 12.2 | 11.38 | 9.7 | Upgrade
|
| Total Current Liabilities | 77.42 | 125.87 | 229.11 | 280.71 | 575.24 | Upgrade
|
| Long-Term Debt | 17.97 | - | - | - | 2,403 | Upgrade
|
| Long-Term Leases | 5.15 | - | 3.16 | 12.65 | 20.31 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 2.08 | 7.08 | 12.08 | Upgrade
|
| Total Liabilities | 100.55 | 125.87 | 234.35 | 300.44 | 3,011 | Upgrade
|
| Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 9,390 | 9,377 | 9,352 | 9,317 | 74.33 | Upgrade
|
| Retained Earnings | -7,205 | -6,697 | -6,522 | -6,038 | -1,874 | Upgrade
|
| Treasury Stock | - | -0.07 | - | - | - | Upgrade
|
| Comprehensive Income & Other | 472.27 | 439.28 | 364.69 | 63.71 | 61.42 | Upgrade
|
| Total Common Equity | 2,657 | 3,119 | 3,195 | 3,343 | -1,738 | Upgrade
|
| Minority Interest | -50.88 | -46.66 | -37.12 | -31.65 | -4.41 | Upgrade
|
| Shareholders' Equity | 2,606 | 3,072 | 3,157 | 3,311 | -1,743 | Upgrade
|
| Total Liabilities & Equity | 2,707 | 3,198 | 3,392 | 3,612 | 1,268 | Upgrade
|
| Total Debt | 28.02 | 3.16 | 12.66 | 21.62 | 2,431 | Upgrade
|
| Net Cash (Debt) | 2,292 | 2,658 | 2,985 | 3,333 | -1,376 | Upgrade
|
| Net Cash Growth | -13.74% | -10.96% | -10.45% | - | - | Upgrade
|
| Net Cash Per Share | 3.14 | 3.65 | 4.13 | 7.59 | -7.20 | Upgrade
|
| Filing Date Shares Outstanding | 731.31 | 729.39 | 727.2 | 720.29 | 706.2 | Upgrade
|
| Total Common Shares Outstanding | 731.31 | 729.39 | 727.2 | 720.29 | 108.65 | Upgrade
|
| Working Capital | 2,337 | 2,657 | 2,848 | 3,133 | 517.61 | Upgrade
|
| Book Value Per Share | 3.63 | 4.28 | 4.39 | 4.64 | -16.00 | Upgrade
|
| Tangible Book Value | 2,477 | 2,852 | 3,048 | 3,333 | -1,751 | Upgrade
|
| Tangible Book Value Per Share | 3.39 | 3.91 | 4.19 | 4.63 | -16.11 | Upgrade
|
| Machinery | 3.71 | 0.34 | 0.34 | 0.34 | 0.34 | Upgrade
|
| Leasehold Improvements | 24.84 | 24.84 | 24.84 | 24.84 | 23.81 | Upgrade
|
Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.